Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review

Department of Oncology, The First Hospital of Jiaxing, First Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang, China.

Special Issues: Advanced Big Data Analysis for Precision Medicine

Gastric cancer is one of the most common gastrointestinal tumors. Most patients have been in advanced stage at diagnosis and lack effective treatment. Molecular targeted drugs have become new therapeutic strategies. MET is an important driving gene for the development of gastric cancer. MET gene amplification and protein over-expression are closely related to the invasion and metastasis, late stage and poor prognosis of gastric cancer. Crizotinib is a small molecule inhibitor against MET. There are few reports of crizotinib in gastric cancer patients with c-MET amplification. This article reports a case of c-MET gene amplification in advanced gastric cancer with liver metastases. After 2 months of treatment with crizotinib, liver lesions were completely relieved and progression-free survival lasted for up to 20 months.
  Figure/Table
  Supplementary
  Article Metrics

Keywords gastric cancer; c-MET; crizotinib

Citation: Guoxin Hou, Binbin Song. Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review. Mathematical Biosciences and Engineering, 2019, 16(5): 5923-5930. doi: 10.3934/mbe.2019296

References

  • 1. P. Tan and K. G. Yeoh, Genetics and molecular pathogenesis of gastric adenocarcinoma, Gastroenterology, 149 (2015), 1153–1162.e1153.
  • 2. P. Chrom, R. Stec and C. Szczylik, Second-line treatment of advanced gastric cancer: Current options and future perspectives, Anticancer Res., 35 (2015), 4575–4583.
  • 3. U. Hacker and F. Lordick, Current standards in the treatment of gastric cancer, Dtsch. Med. Wochenschr., 140 (2015), 1202–1205.
  • 4. M. Orditura, G. Galizia, V. Sforza, et al., Treatment of gastric cancer, World J. Gastroenterol., 20 (2014), 1635–1649.
  • 5. A. Bilici, Treatment options in patients with metastatic gastric cancer: current status and future perspectives, World J. Gastroenterol., 20 (2014), 3905–3915.
  • 6. L. Marano, R. Chiari, A. Fabozzi, et al., c-Met targeting in advanced gastric cancer: An open challenge, Cancer Lett., 365 (2015), 30–36.
  • 7. C. A. Bradley, M. Salto-Tellez, P. Laurent-Puig, et al., Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges, Nat. Rev. Clin. Oncol., 14 (2017), 562–576.
  • 8. H. Kawakami and I. Okamoto, MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy, Gastric. Cancer, 19 (2016), 687–695.
  • 9. S. H. Ou, E. L. Kwak, C. Siwak-Tapp, et al., Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification, J. Thorac. Oncol., 6 (2011), 942–946.
  • 10. Y. J. Liu, D. Shen, X. Yin, et al., HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma, Br. J. Cancer, 110 (2014), 1169–1178.
  • 11. W. Okamoto, I. Okamoto, T. Arao, et al., Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification, Mol. Cancer Ther., 11 (2012), 1557–1564.
  • 12. K. Nanki, K. Toshimitsu, A. Takano, et al., Divergent routes toward wnt and r-spondin niche independency during human gastric carcinogenesis, Cell, 174 (2018), 856–869.e817.
  • 13. K. Muro, H. C. Chung, V. Shankaran, et al., Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial, Lancet Oncol., 17 (2016), 717–726.
  • 14. J. Li, S. Qin, J. Xu, et al., Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial, J. Clin. Oncol., 31 (2013), 3219–3225.
  • 15. K. Han, J. Jin, M. Maia, et al., Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial, Aaps J., 16 (2014), 1056–1063.
  • 16. C. S. Fuchs, J. Tomasek, C. J. Yong, et al., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383 (2014), 31–39.
  • 17. D. Kazandjian, G. M. Blumenthal, H. Y. Chen, et al., FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements, Oncologist, 19 (2014), e5–11.
  • 18. A. Drilon, F. Cappuzzo, S. I. Ou, et al., Targeting MET in lung cancer: Will expectations finally be MET?, J. Thorac. Oncol., 12 (2017), 15–26.
  • 19. C. Birchmeier, W. Birchmeier, E. Gherardi, et al., Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol., 4 (2003), 915–925.
  • 20. J. G. Christensen, J. Burrows and R. Salgia, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Lett., 225 (2005), 1–26.
  • 21. H. Amemiya, K. Kono, J. Itakura, et al., c-Met expression in gastric cancer with liver metastasis, Oncology, 63 (2002), 286–296.
  • 22. G. R. Blumenschein, Jr., G. B. Mills and A. M. Gonzalez-Angulo, Targeting the hepatocyte growth factor-cMET axis in cancer therapy, J. Clin. Oncol., 30 (2012), 3287–3296.
  • 23. D. V. Catenacci, A. Ang, W. L. Liao, et al., MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma, Cancer, 123 (2017), 1061–1070.
  • 24. O. O. Ogunwobi, W. Puszyk, H. J. Dong, et al., Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma, PLoS One, 8 (2013), e63765.
  • 25. L. Goyal, M. D. Muzumdar and A. X. Zhu, Targeting the HGF/c-MET pathway in hepatocellular carcinoma, Clin. Cancer Res., 19 (2013), 2310–2318.
  • 26. M. S. Wong, S. M. Sidik, R. Mahmud, et al., Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects, Clin. Exp. Pharmacol. Physiol., 40 (2013), 307–319.
  • 27. J. R. Sierra and M. S. Tsao, c-MET as a potential therapeutic target and biomarker in cancer, Ther. Adv. Med. Oncol., 3 (2011), S21–35.
  • 28. K. H. Lee, E. Y. Choi, M. S. Hyun, et al., Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer, Korean J. Intern. Med., 21 (2006), 20–27.
  • 29. J. Lee, J. W. Seo, H. J. Jun, et al., Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target, Oncol. Rep., 25 (2011), 1517–1524.
  • 30. W. S. Park, R. R. Oh, Y. S. Kim, et al., Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas, Apmis, 108 (2000), 195–200.
  • 31. S. Y. Ha, J. Lee, S. Y. Kang, et al., MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas, Mod. Pathol., 26 (2013), 1632–1641.
  • 32. J. Zhao, X. Zhang and Y. Xin, Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas, Histol. Histopathol., 26 (2011), 1111–1120.
  • 33. K. Sotoudeh, F. Hashemi, Z. Madjd, et al., The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays, Diagn. Pathol., 7 (2012), 57.
  • 34. Z. Peng, Y. Zhu, Q. Wang, et al., Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis, PLoS One, 9 (2014), e84502.
  • 35. J. K. Lennerz, E. L. Kwak, A. Ackerman, et al., MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib, J. Clin. Oncol., 29 (2011), 4803–4810.
  • 36. Y. K. Kang, M. H. Ryu, C. Yoo, et al., Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer, Cancer Chemother. Pharmacol., 67 (2011), 1435–1443.
  • 37. S. Y. Oh, H. C. Kwon, S. H. Jeong, et al., A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer, Invest New Drugs, 30 (2012), 350–356.
  • 38. J. Li, S. Qin, J. Xu, et al., Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, J. Clin. Oncol., 34 (2016), 1448–1454.

 

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved